Tuesday 29th March Plenary sessions are shared across all conferences


Partnerships, Tuesday 29 March 2016

Dr Gregory A. Poland

Chair’s opening remarks

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation
Dr Gregory A. Poland

Vaccinomics and vaccinology 3.0 – The way forward

  • Vaccinomics, adversomics and the immune response network theory: Individualized vaccinology in the 21st century
  • New understandings of how vaccines stimulate immune responses, new biomarkers for vaccine response, and facilitate the understanding of what genetic and other factors might be responsible for rare side effects due to vaccines
  • Integrating increasingly complex high throughput data into descriptive and predictive equations for immune responses to vaccines
Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation
Dr. Leonard Friedland

Vaccine adjuvant science: Understanding modern vaccines

  • Novel adjuvant systems under investigation by GSK and safety considerations
  • Learning and challenges in combining adjuvants including pre-clinical and clinical experience
  • Experience and considerations for use in special populations
  • Potential application of adjuvants to future vaccines (experience with adjuvanted investigational zoster vaccine), and adjuvant communication to healthcare providers and patients
Dr. Leonard Friedland, VP, Scientific Affairs and Public Health Vaccines, North America, GSK
Dr Peter Hotez

Developing a new generation of neglected disease vaccines

  • New human hookworm and schistosomiasis vaccines now in clinical trials and earlier stage vaccines for Chagas disease, leishmaniasis
  • Building vaccine development capacity in critical areas threatened by poverty and conflict, including ISIS held territories with the White House and State Department US Science Envoy
Dr Peter Hotez, President of the Sabin Vaccine Institute and Dean of National School of Tropical Medicine, Baylor College of Medicine

Networking Coffee Break



Vaccinating the anti-vaxxers
Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences

The need for a vaccine development fund 
Prof Stanley A. Plotkin, Emeritus Professor, University of Pennsylvania & Executive Advisor, Sanofi Pasteur
Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic

How can the pharma/CRO industry better collaborate with the site networks?
Lynlee Burton, Director of Project Delivery – Vaccines, PRA Health Sciences

Practical issues around inclusion/exclusion criteria and protocol design with their impact on time-lines, data collection, and quality of subjects
Prof William B. Smith, Founder, President, and Principal Investigator NOCCR/VRG

Overcoming hurdles in technology transfer & IP
Dr Mukul Ranjan, Senior Advisor for Innovation and Technology Transfer, National Institute of Allergy and Infectious Diseases

Considerations for global clinical vaccine studies
Dr Cynthia Dukes, VP Global Project Management, Vaccines, Infectious Diseases, Women’s Health and Primary Care, ICON Clinical Research

New approaches to accessing patient populations: Adults in G8 markets, middle income countries and helping Gavi-funded governments reach the fifth child
Tara Azimi, Expert Associate Principal, McKinsey & Company
Aliza Apple, Engagement Manager, McKinsey & Company

Designing effective processes to enable scalability of vaccine products
Dr Joseph G. Joyce, Director, Vaccine Process Development, Merck Research Laboratories

A Transition to Targeted or “Smart” Vaccines: How Understanding Commensal Colonization Can Lead to Selective Vaccination
Dr Blaine Pfeifer, Associate Professor, Chemical and Biological Engineering Department, State University of New York at Buffalo

The issue of virally-induced cancers: Barriers to awareness
Dr Lopa Mishra, Director, Center for Translational Research Department of Surgery and GWU Cancer Center, George Washington University

From surrogate markers to predictive biomarkers of vaccine efficacy: How realistic is to enhance the blood markers beyond serum antibody?
Dr Ali Harandi, Associate Professor, Lab head, University of Gothenburg

Challenges and Opportunities in Conducting Clinical Trials in West Africa

Dr David Hoover, Senior Medicial Advisor, Clinical RM
Dr Kevin J. Gilligan, Senior Scientific Advisor, Clinical RM

Zika virus: Challenges for medical countermeasure development
Dr Robert Malone, CEO and Consultant, RW Malone MD, LLC
Pre-clinical biomarkers of safety and efficacy in vaccine design and development
Dr Michael Vajdy, Co-Founder, President and Chief Scientific Officer, Epito Genesis Inc
Adjuvants and technology advancements driving vaccine R&D
Dr Michel De Wilde, Former Senior Vice President R&D of Sanofi Pasteur & Owner, MDW Consultant LLC


Networking Lunch

Dr Heather Sings

An interactive point-count point discussion: Polysaccharide vs conjugate pneumococcal vaccine

  • Policy recommendations for pneumococcal vaccination around the world
  • Amount of disease caused by vaccine serotypes
  • Indirect protection in adults from pediatric use of PCV13
  • Vaccine effectiveness and other immunologic considerations
  • Carriage, duration of protection and cost effectiveness
Dr Heather Sings, Senior Director and Medical Lead, Pneumococcal Vaccines, Pfizer
Dr Melvin Kohn, Medical Director for Adult Vaccines, Merck Vaccines
Dr Laura York

An interactive joint presentation on the FDA approved meningococcal B vaccines

  • The science behind different approaches
  • Discussing the different approaches in getting FDA approval
  • Predictions of effectiveness in additional strains
Dr Laura York, VP, Global Meningococcal Vaccines, Medical Development and Scientific/Clinical Affairs, Pfizer
Dr Rino Rappuoli, Chief Scientist, GSK Vaccines
Dr Wellington Sun

Regulating vaccines at the FDA: Development and licensure of Ebola vaccines

  • What have we learnt from the Ebola crisis?
  • How quickly can we work together to help speed up the process of licensure?
  • How will we respond to the next threat?
Dr Wellington Sun, Director Division of Vaccines and Related Products Applications CBER, U.S. Food and Drug Administration

Networking coffee break

James Mansi

A century of vaccine development & innovation: Ensuring novel influenza vaccines are available to meet the needs of diverse patients groups

  • Vaccines developed for the young, the old, and everyone in between
  • Moving from traditional needle and syringe to innovative needle-free delivery systems
  • Transition from traditional trivalent flu vaccines to quadrivalent, cell culture based, and adjuvanted vaccines
James Mansi, Global Head, Medical Affairs, Novartis Influenza Vaccines
Dr Gary Nabel

What is the vision for a HIV vaccine? Has it changed in the last decade?

  • Update on the clinical trials and their progress
  • Has the sense of urgency for a HIV vaccine lost its momentum with effective preventative methods that can stop/limit transmission
  • Could HIV eliminate itself eventually?
  • The vision for a vaccine to replace all preventative methods 
Dr Gary Nabel, Senior Vice President and Chief Scientific Officer, Sanofi Inc
Rahul Singhvi

The future sustainability of vaccines - What pressure does the industry suffer from that could prevent access to vaccine?

-How will the industry look in 10 years? Understanding the industry dynamics and factors that will give you a competive advantage
-Addressing the obstacles poised in market access and manufacturing
-How to treat the vaccine industry differently to the pharmaceutical industry as a whole, using value based pricing as an example
Rahul Singhvi, Chief Operating Officer, Takeda Vaccines, Inc.
Dr Gregory A. Poland

Chair’s closing remarks and close of congress day 1

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation

Pre-Awards Networking Drinks Reception


Gala Dinner & ViE Awards Ceremony

last published: 24/Mar/16 11:26



Partnerships, Wednesday 30 March 2016

Dr Jim Tartaglia

Chair’s opening remarks

Dr Jim Tartaglia, Vice President New Vaccine Project Head North America, Sanofi Pasteur
Panel discussion

Panel: Big Pharma Industry's external collaborative research and partnering opportunities for vaccine development

  • Identify and assess technology platforms and vaccine candidates of interest:  Global breadth in new alliance strategies
  • Clinical co-development to fast track vaccine research and commercial success
  • Opportunities with academia, public-private partnerships, biotech and other pharma
  • Regional strategies vs global strategies
Dr Bill Hearl, Founder And Chief Executive Officer, Immunomic Therapeutics
Ms Marian Wentworth, Vice President of Global Vaccines Strategy and Innovation, Merck and Co Inc
Dr Roman Chicz, Associate Vice President and Global Head Of External Research and Development, Sanofi Pasteur Inc
Dr John Boslego, Head of Development, Takeda
Prof Annie De Groot

Biotech showcase 1: Immune camouflage: Improving vaccine design through In silico identification of immunoevasion mechanisms

  • Why are vaccines for chronic infection often unavailable?
  • Identifying pathogen mechanisms that allow evasion of host immune responses
  • Finding suppression of viral-specific effector CD4+ and CD8+ T cells by stimulating regulatory T cells (Tregs)
  • The potential of viral epitopes with substantial homology to activate Tregs 
Prof Annie De Groot, Chief Executive Officer, Chief Scientific Officer and Director, EpiVax Inc
Dr Nikolai Petrovsky

Biotech showcase 2: Tools and technologies to enhance vaccine effectiveness

  • Why do so many vaccines fail at the clinical trial phase
  • Are the right antigens failing because they are being combined with the wrong adjuvants or delivery approaches
  • Are we using the right readouts for vaccine efficacy in our animal models
  • How a novel polysaccharide adjuvant approach can be used to transform vaccine efficacy
Dr Nikolai Petrovsky, Chairman, Vaxine Pty.

Networking coffee break

Dr James Dale

Biotech showcase 3: Insights into the Group A Streptococcal vaccine trial

  • What have been the biggest challenges in developing the Strep A Vaccine?
  • Novel techniques that we have used to develop a complex multivalent vaccine
  • Unexpected positive results related to cross-protection against non-vaccine types
  • The potential global impact of the Strep A Vaccine
Dr James Dale, CSO, Vaxent
Mr Doug Brough

Biotech showcase 4: Novel gorilla adenovector vaccine platform for superior immune responses

  • High, durable antibody and T cell responses from a single administration
  • No pre-existing immunity and ability to boost with repeat administration
  • Leverages GenVec’s well-characterized production systems
Mr Doug Brough, Chief Scientific Officer, Genvec
Dr Ming-Chung Kan

Biotech showcase 5: New vaccine platform increasing adaptive immune responses

  • Stimulating both humoral and cellular immunity by fusing a short peptide to antigen
  • Developing this technology
  • Using this vaccine platform for various purposes
Dr Ming-Chung Kan, Founder, vaxsia
Dr Drew Hannaman

Biotech showcase 6: Electroporation mediated DNA immunization: Clinical progress and technology development

-    Presentation of results from clinical trials of electroporation mediated DNA vaccine delivery in oncology and infectious disease applications
-    Effect of route of administration on safety, tolerability, and vaccine immunogenicity 
-    Development of devices suitable for commercial product deployment
Dr Drew Hannaman, Vice President of Research and Development, Ichor Medical Systems
Adam Sabow

Solving the innovation challenge: Balancing public health and economic imperatives in the vaccine industry

  • Progression and relevance of the current pipeline to address unmet needs
  • Headwinds and tailwinds in innovation incl. business economics and market certainty
  • Recommendations on solutions to achieve public health objectives and sustainable economics in tandem
Adam Sabow, Director, McKinsey & Company
Tara Azimi, Associate Principal, Mckinsey & Company

Networking Lunch

Dr Peter Khoury

Areas of interest for global health R&D funding by the Bill & Melinda Gates Foundation

  • Our strategy when investing in vaccine technology
  • Working with partners to scale-up access to vaccines, medicines and diagnostics
  • Accessibility and affordability 
Dr Peter Khoury, Senior Program Officer, The Bill & Melinda Gates Foundation
Alex Zisson

Investor panel: Hear from a number of VCs to better understand what they are looking for before they invest

  • What stage do they invest in vaccine biotechs and why?
  • Do biotechs also need to demonstrate PhII?
  • What terms do they look for to leverage in your invest in particular?
  • What could a biotech demonstrate to investors earlier to gain their support?
Alex Zisson, Partner, Thomas, McNerney & Partners
Ms Tania Fernandez, Founder and Chief Executive Officer, DreamCatcher Ventures
Stephen Nagler, Executive Director, MedPro Investors LLC
Christopher Egerton-Warburton, Fund Manager, Global Health Investment Fund

Networking coffee break

Dr Jim Tartaglia

How to make public-private partnerships work

  • When is it best to engage in public-private partnerships?
  • Building a collaborative structure where all parties can share the same common goal and long-term investment as well as appropriate responsibility and risk
  • Learning from past successes to support future partnerships
Moderator: Dr Jim Tartaglia, Vice President New Vaccine Project Head North America, Sanofi Pasteur
Mr Paulo Sison, Director, Innovative Finance & Private Sector Partnerships, GAVI Alliance
Dr Michael Kurilla, Director, N.I.A.I.D. N.I.H.
Dr Kutub Mahmood, Director, PATH
Prof Mark Prausnitz

Industry and early stage biotech/academia collaborations

  • Building long-term partnerships to advance research and pre-clinical data
  • Case studies of successful and harmonious alliances with not-for-profits, industry and academia
  • Pooling resources and knowledge to expand applicable techniques to new vaccines
Prof Mark Prausnitz, Regents’ Professor, Georgia Institute of Technology
Dr S D Ravetkar

Vaccine landscape in developing countries

  • Immunization scenario.
  • Vaccine global needs and supply
  • Role of developing countries
  • What are developing countries looking for in partnerships and vaccine specific diseases?
  • How is vaccine development and manufacture changing in India?
  • India's leadership position in vaccine manufacturing and advancements.

Dr S D Ravetkar, Executive Director, Serum Institute of India Ltd
last published: 24/Mar/16 11:26



Partnerships, Thursday 31 March 2016


Networking coffee break


Networking Lunch

Dr Gregory A. Poland

Chair’s opening remarks

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation
Dr Thomas Breuer

ABCs of Supply and Demand: Creating the Future

-    Appreciating the intricacies of the vaccine industry: Roles and structure of the Industry, R&D and manufacturing cycles    
-    Industry future: Health solutions and business challenges
-    How we achieve business sustainability and meet global vaccine needs
-    Measuring and recognizing the full economic and social value of vaccines
-    What the industry, partners and governments need to do
Dr Thomas Breuer, Senior Vice President, Chief Medical Officer, G.S.K. Vaccines
Dr Carol J. Baker

Do we need a new strategy for maternal immunization?

  • Are vaccines that benefit the baby more than the mother acceptable?
  • Have we progressed in our understanding of maternal and neonatal vaccine immunology?
  • Where are we with development of vaccines that affect maternal and infant health (e.g., group B Streptococcus, respiratory syncytial virus, pertussis and influenza)?
Dr Carol J. Baker, Head of Infectious Disease Professor of Pediatrics, Baylor College of Medicine
Dr Jerome Kim

A MERS vaccine: Doing research and vaccine development preemptively

  • For-profit vaccine companies will find it difficult to make vaccines that are not used except in an emergency
  • Governments can and do fund the production of vaccines that are not commercially viable but bear the risks of discovery and the burden of development
  • MERS is not the herald of an impending epidemic apocalypse but public health, and the vaccines necessary to maintain it, is not free or easy
Dr Jerome Kim, Director-General, International Vaccine Institute
Dr Gregory A. Poland

Chair’s closing remarks and close of congress

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation
last published: 24/Mar/16 11:26